期刊
NATURE COMMUNICATIONS
卷 12, 期 1, 页码 -出版社
NATURE RESEARCH
DOI: 10.1038/s41467-021-21858-1
关键词
-
资金
- vivo Imaging shared resource at UCSD (Ultrasound machine grant) [S10 OD02182]
- Alexandrina M. McAfee Trust Foundation
- National Cancer Institute of NIH [R01CA152327]
- Career Development Award from American Association of Cancer Research/Pancreatic Cancer Action Network
- European Regional Development Fund [2014-2020.4.01.15-0012]
- European Research Council grant GLIOGUIDE from European Regional Development Fund
- Estonian Research Council [PRG230, EAG79]
- Research for a Cure of Pancreatic Cancer Fund
- NIH T32 Fellowship [CA121949]
- [R01CA167174]
- [R01CA155620]
- [KL2TR001112-02]
CAFs induce beta 5 integrin expression in tumor cells in a TGF-beta dependent manner, making them an efficient drug delivery target for the tumor-penetrating peptide iRGD. Knocking out beta 5 integrins in tumor cells suppresses the capacity of iRGD to deliver payloads, leading to reduced disease burden and prolonged survival in mouse models. iRGD penetration into the desmoplastic PDAC microenvironment requires beta 5 integrin expression on tumor cells mediated by CAFs-derived TGF-beta, and iRGD-based combination therapy is effective in PDAC mouse models.
Pancreatic ductal adenocarcinoma (PDAC) is characterized by marked desmoplasia and drug resistance due, in part, to poor drug delivery to extravascular tumor tissue. Here, we report that carcinoma-associated fibroblasts (CAFs) induce beta 5 integrin expression in tumor cells in a TGF-beta dependent manner, making them an efficient drug delivery target for the tumor-penetrating peptide iRGD. The capacity of iRGD to deliver conjugated and co-injected payloads is markedly suppressed when beta 5 integrins are knocked out in the tumor cells. Of note, beta 5 integrin knock-out in tumor cells leads to reduced disease burden and prolonged survival of the mice, demonstrating its contribution to PDAC progression. iRGD significantly potentiates co-injected chemotherapy in KPC mice with high beta 5 integrin expression and may be a powerful strategy to target an aggressive PDAC subpopulation. The iRGD tumor-penetrating peptide can achieve tumor specific drug delivery but whether and how it can penetrate into desmoplastic tumors is unknown. Here, the authors show that beta 5 integrin expression on tumor cells, mediated by CAFs-derived TGF-beta, is required for iRGD penetration into the desmoplastic PDAC microenvironment and that iRGD-based combination therapy is effective in PDAC mouse models.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据